Inhibikase 201 trial ~75% enrolled; expects completion by mid-June 2024

Inhibikase Therapeutics, Inc.

201 Trial (risvodetinib) ~75% enrolled, 30 patients left; enrollment completion expected mid-June 2024.
Plan to initiate a 12-month extension study; requires additional capital.
Pre-IND meeting with FDA for IkT-001Pro in PAH completed; pre-NDA for cancer indications held.
Submitted grants to NINDS/NIH for biomarker development including new monoclonal antibody.
Expects end-of-Phase 2 meeting with FDA by end of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.